New Drug For Rapidly Lethal Form Of Prostate Cancer
Neuroendocrine prostate cancer (NEPC) is a rapidly lethal form of advanced prostate cancer that does not respond to hormonal therapy. Fund research to develop inhibitors of BRN2, a driver of NEPC, as a possible new treatment option for these patients.
Developing New Treatments for Lethal Neuroendocrine Prostate Cancer
Neuroendocrine prostate cancer (NEPC) arises in a subset of patients who relapse following androgen receptor (AR)-targeted therapy.
There is an urgent need to develop new and effective treatments for patients with this highly aggressive and lethal subtype of prostate cancer.
Prostate Cancer Foundation researchers have identified the neural protein BRN2 as a major driver and a promising therapeutic target in NEPC.
Prostate Cancer Foundation researchers will develop clinical trial-ready inhibitors of BRN2 with optimal activity and safety.
Biomarkers will be developed to identify which patients will benefit most from this treatment.